gyki 52466 has been researched along with Anterior Circulation Transient Ischemic Attack in 7 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "GYKI 52466 failed to inhibit this increase." | 1.29 | Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia. ( Arvin, B; Chapman, AG; Graham, JL; Lekieffre, D; Meldrum, BS; Moncada, C, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elger, B | 1 |
| Huth, A | 1 |
| Neuhaus, R | 1 |
| Ottow, E | 1 |
| Schneider, H | 1 |
| Seilheimer, B | 1 |
| Turski, L | 1 |
| Li, H | 1 |
| Buchan, AM | 1 |
| Arvin, B | 3 |
| Lekieffre, D | 1 |
| Graham, JL | 1 |
| Moncada, C | 3 |
| Chapman, AG | 1 |
| Meldrum, BS | 3 |
| Weiser, T | 1 |
| Brenner, M | 1 |
| Palluk, R | 1 |
| Bechtel, WD | 1 |
| Ceci, A | 1 |
| Brambilla, A | 1 |
| Ensinger, HA | 1 |
| Sagrada, A | 1 |
| Wienrich, M | 1 |
| Gyertyán, I | 1 |
| Gigler, G | 1 |
| Simó, A | 1 |
| Le Peillet, E | 2 |
| Chapman, A | 1 |
7 other studies available for gyki 52466 and Anterior Circulation Transient Ischemic Attack
| Article | Year |
|---|---|
Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
Topics: Acute Disease; Animals; Benzodiazepines; Binding, Competitive; Brain Infarction; Cells, Cultured; Di | 2005 |
Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Benzodiazepi | 1993 |
Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia.
Topics: Amino Acids; Animals; Anti-Anxiety Agents; Aspartic Acid; Benzodiazepines; Cerebral Cortex; Corpus S | 1994 |
BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anti-Anxiety Agents; Anticonvulsa | 1999 |
The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Body Temperature; Chlorpromazine; Excitatory Amino Ac | 1999 |
The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cell Death; Cerebral Cortex; Corpus Striatum; Excitat | 1992 |
GYKI 52466 blocks the increase in extracellular glutamate induced by ischaemia.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Cerebral Cortex; Corpus Striatum; Glutamates; Glutami | 1992 |